Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients.

Avedissian S, Miglis C, Kubin CJ, Rhodes NJ, Yin MT, Cremers S, Prickett M, Scheetz MH.

Pharmacotherapy. 2018 May 25. doi: 10.1002/phar.2129. [Epub ahead of print]

PMID:
29800496
2.

Knowledge, Attitudes, and Practices Regarding Antimicrobial Use and Stewardship Among Prescribers at Acute-Care Hospitals.

Salsgiver E, Bernstein D, Simon MS, Eiras DP, Greendyke W, Kubin CJ, Mehta M, Nelson B, Loo A, Ramos LG, Jia H, Saiman L, Furuya EY, Calfee DP.

Infect Control Hosp Epidemiol. 2018 Mar;39(3):316-322. doi: 10.1017/ice.2017.317. Epub 2018 Feb 6.

PMID:
29402339
3.

Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.

Miglis C, Rhodes NJ, Avedissian SN, Kubin CJ, Yin MT, Nelson BC, Pai MP, Scheetz MH.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01475-17. doi: 10.1128/AAC.01475-17. Print 2018 Mar.

4.

Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples.

Kubin CJ, Nelson BC, Miglis C, Scheetz MH, Rhodes NJ, Avedissian SN, Cremers S, Yin MT.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01493-17. doi: 10.1128/AAC.01493-17. Print 2018 Mar.

5.

Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.

Gomez-Simmonds A, Nelson B, Eiras DP, Loo A, Jenkins SG, Whittier S, Calfee DP, Satlin MJ, Kubin CJ, Furuya EY.

Antimicrob Agents Chemother. 2016 May 23;60(6):3601-7. doi: 10.1128/AAC.03007-15. Print 2016 Jun.

6.

Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients.

Pouch SM, Kubin CJ, Satlin MJ, Tsapepas DS, Lee JR, Dube G, Pereira MR.

Transpl Infect Dis. 2015 Dec;17(6):800-9. doi: 10.1111/tid.12450. Epub 2015 Nov 5.

7.

Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.

Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, Whittier S, Calfee DP, Furuya EY, Kubin CJ.

Antimicrob Agents Chemother. 2015 Nov;59(11):7000-6. doi: 10.1128/AAC.00844-15. Epub 2015 Aug 31.

8.

Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Espinel-Ingroff A, Alvarez-Fernandez M, Cantón E, Carver PL, Chen SC, Eschenauer G, Getsinger DL, Gonzalez GM, Govender NP, Grancini A, Hanson KE, Kidd SE, Klinker K, Kubin CJ, Kus JV, Lockhart SR, Meletiadis J, Morris AJ, Pelaez T, Quindós G, Rodriguez-Iglesias M, Sánchez-Reus F, Shoham S, Wengenack NL, Borrell Solé N, Echeverria J, Esperalba J, Gómez-G de la Pedrosa E, García García I, Linares MJ, Marco F, Merino P, Pemán J, Pérez Del Molino L, Roselló Mayans E, Rubio Calvo C, Ruiz Pérez de Pipaon M, Yagüe G, Garcia-Effron G, Guinea J, Perlin DS, Sanguinetti M, Shields R, Turnidge J.

Antimicrob Agents Chemother. 2015 Nov;59(11):6725-32. doi: 10.1128/AAC.01250-15. Epub 2015 Aug 17.

9.

Appropriateness of gram-negative agent use at a tertiary care hospital in the setting of significant antimicrobial resistance.

Vora NM, Kubin CJ, Furuya EY.

Open Forum Infect Dis. 2015 Feb 19;2(1):ofv009. doi: 10.1093/ofid/ofv009. eCollection 2015 Jan.

10.

Calming the "perfect storm" in methicillin-resistant Staphylococcus aureus bacteremia: a call for a more balanced discussion.

Eschenauer GA, Nagel JL, Kubin CJ, Lam SW, Patel TS, Potoski BA.

Clin Infect Dis. 2015 Feb 15;60(4):670-1. doi: 10.1093/cid/ciu883. Epub 2014 Nov 3. No abstract available.

PMID:
25371485
11.

Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.

Patel SJ, Oliveira AP, Zhou JJ, Alba L, Furuya EY, Weisenberg SA, Jia H, Clock SA, Kubin CJ, Jenkins SG, Schuetz AN, Behta M, Della-Latta P, Whittier S, Rhee K, Saiman L.

Am J Infect Control. 2014 Jun;42(6):626-31. doi: 10.1016/j.ajic.2014.01.027. Epub 2014 Apr 13.

12.

Comparison of 3 severity criteria for Clostridium difficile infection.

Gomez-Simmonds A, Kubin CJ, Furuya EY.

Infect Control Hosp Epidemiol. 2014 Feb;35(2):196-9. doi: 10.1086/674851. Epub 2013 Dec 23.

13.

Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.

Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ.

Antimicrob Agents Chemother. 2014;58(4):1897-906. doi: 10.1128/AAC.02163-13. Epub 2014 Jan 6.

14.

Risk factors associated with Clostridium difficile infection after kidney and pancreas transplantation.

Shah SA, Tsapepas DS, Kubin CJ, Martin ST, Mohan S, Ratner LE, Pereira M, Kapur S, Dadhania D, Walker-McDermott JK.

Transpl Infect Dis. 2013 Oct;15(5):502-9. doi: 10.1111/tid.12113. Epub 2013 Jul 25.

PMID:
23890202
15.

In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.

Clock SA, Tabibi S, Alba L, Kubin CJ, Whittier S, Saiman L.

Diagn Microbiol Infect Dis. 2013 Jul;76(3):343-6. doi: 10.1016/j.diagmicrobio.2013.03.014. Epub 2013 Apr 17.

PMID:
23601454
16.

Clinicians' knowledge, attitudes, and practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units.

Zhou JJ, Patel SJ, Jia H, Weisenberg SA, Furuya EY, Kubin CJ, Alba L, Rhee K, Saiman L.

Infect Control Hosp Epidemiol. 2013 Mar;34(3):274-83. doi: 10.1086/669524. Epub 2013 Jan 24.

17.

High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.

Thomas TA, Broun EC, Abildskov KM, Kubin CJ, Horan J, Yin MT, Cremers S.

Ther Drug Monit. 2012 Aug;34(4):398-405. doi: 10.1097/FTD.0b013e31825c827a.

18.

Lack of significant variability among different methods for calculating antimicrobial days of therapy.

Kubin CJ, Jia H, Alba LR, Yoko Furuya E.

Infect Control Hosp Epidemiol. 2012 Apr;33(4):421-3. doi: 10.1086/664770.

PMID:
22418642
19.

Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.

Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT.

J Infect. 2012 Jul;65(1):80-7. doi: 10.1016/j.jinf.2012.01.015. Epub 2012 Feb 2.

PMID:
22326553
20.

Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.

Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP.

Antimicrob Agents Chemother. 2011 Dec;55(12):5893-9. doi: 10.1128/AAC.00387-11. Epub 2011 Oct 3.

21.

Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest.

Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, Jenkins SG, Saiman L, Kubin CJ.

J Clin Microbiol. 2011 May;49(5):1795-8. doi: 10.1128/JCM.02534-10. Epub 2011 Mar 2. Erratum in: J Clin Microbiol. 2013 Jul;51(7):2472.

22.

Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.

Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ.

Diagn Microbiol Infect Dis. 2010 Jun;67(2):180-4. doi: 10.1016/j.diagmicrobio.2010.02.001. Epub 2010 Mar 31.

PMID:
20356699
23.

The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection.

Kludze-Forson M, Eschenauer GA, Kubin CJ, Della-Latta P, Lam SW.

Med Mycol. 2010 Mar;48(2):436-9. doi: 10.3109/13693780903208256.

PMID:
20141378
24.

A review of antimicrobial control strategies in hospitalized and ambulatory pediatric populations.

Patel SJ, Larson EL, Kubin CJ, Saiman L.

Pediatr Infect Dis J. 2007 Jun;26(6):531-7. Review.

PMID:
17529873
25.

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.

Weems JJ Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R, Moore T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG Jr.

Antimicrob Agents Chemother. 2006 Aug;50(8):2751-5.

26.

Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ.

J Antimicrob Chemother. 2004 Aug;54(2):566-9. Epub 2004 Jul 21.

PMID:
15269195
27.

Antimicrobial control programs.

Kubin CJ.

Semin Perinatol. 2002 Oct;26(5):379-86. Review.

PMID:
12452510
28.

Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature.

Zeana C, Kubin CJ, Della-Latta P, Hammer SM.

Clin Infect Dis. 2001 Aug 15;33(4):477-82. Epub 2001 Jul 11. Review.

PMID:
11462183
29.

Delayed-onset ticlopidine-induced cholestatic jaundice.

Kubin CJ, Sherman O, Hussain KB, Feinman L.

Pharmacotherapy. 1999 Aug;19(8):1006-10.

PMID:
10453975

Supplemental Content

Loading ...
Support Center